These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18353413)

  • 41. Identification of biomarkers indicating cellular changes after treatment of neuronal cells with the C3 exoenzyme from Clostridium botulinum using the iTRAQ protocol and LC-MS/MS analysis.
    Muetzelburg MV; Hofmann F; Just I; Pich A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(13):1344-51. PubMed ID: 19109081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles.
    Cadron I; Van Gorp T; Amant F; Vergote I; Moerman P; Waelkens E; Daemen A; Van De Plas R; De Moor B; Zeillinger R
    Anticancer Res; 2009 Apr; 29(4):1039-45. PubMed ID: 19414343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Use of laser capture microdissection and surface-enhanced laser desorption ionization time-of-flight mass spectrometry to screen differential proteins in lung adenocarcinoma and lung squamous carcinoma].
    Tian YX; Yang SY; Nan YD; Zhang W; Zhou B; Bu LN; Huo SF; Yu JK; Zheng S
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(3):145-8. PubMed ID: 18361807
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proteomic approaches in lung cancer biomarker development.
    Cho JY; Sung HJ
    Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
    Xu G; Xiang CQ; Lu Y; Kang XN; Liao P; Ding Q; Zhang YF
    Cancer Lett; 2009 Sep; 282(2):205-13. PubMed ID: 19362769
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Profiles of low-molecular proteome spectrum obtained through SELDI-TOF mass spectrometry in the sera of patients with metastatic malignant melanoma: pilot study].
    Lakomý R'; Greplová K; Pilný R; Budinská E; Valík D; Poprach A; Nemecek R; Vyzula R
    Klin Onkol; 2009; 22(5):228-32. PubMed ID: 19886361
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analytical and statistical approaches to metabolomics research.
    Issaq HJ; Van QN; Waybright TJ; Muschik GM; Veenstra TD
    J Sep Sci; 2009 Jul; 32(13):2183-99. PubMed ID: 19569098
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of genomic and proteomic technologies to early detection of cancer.
    Ardekani AM; Akhondi MM; Sadeghi MR
    Arch Iran Med; 2008 Jul; 11(4):427-34. PubMed ID: 18588376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proteomics and metabolomics combined in cardiovascular research.
    Mayr M; Madhu B; Xu Q
    Trends Cardiovasc Med; 2007 Feb; 17(2):43-8. PubMed ID: 17292045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proteomic profiling of CHO cells with enhanced rhBMP-2 productivity following co-expression of PACEsol.
    Meleady P; Henry M; Gammell P; Doolan P; Sinacore M; Melville M; Francullo L; Leonard M; Charlebois T; Clynes M
    Proteomics; 2008 Jul; 8(13):2611-24. PubMed ID: 18546152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Detection of tissue protein biomarkers by surface enhanced laser desorption/ionization-time of flight-mass spectrometry in patients with mycosis fungoides].
    Liu J; Zheng YH; Zhou YF; Zhang JZ; Wang BX
    Zhonghua Yi Xue Za Zhi; 2009 Jan; 89(2):100-4. PubMed ID: 19489271
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CE MALDI-TOF/TOF MS for multiplexed quantification of proteins in human ventricular cerebrospinal fluid.
    Zuberovic A; Wetterhall M; Hanrieder J; Bergquist J
    Electrophoresis; 2009 May; 30(10):1836-43. PubMed ID: 19441030
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum proteomics of glioma: methods and applications.
    Somasundaram K; Nijaguna MB; Kumar DM
    Expert Rev Mol Diagn; 2009 Oct; 9(7):695-707. PubMed ID: 19817554
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analytical nanobiotechnology for medicine diagnostics.
    Archakov AI; Ivanov YD
    Mol Biosyst; 2007 May; 3(5):336-42. PubMed ID: 17460792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolomics: from pattern recognition to biological interpretation.
    Weckwerth W; Morgenthal K
    Drug Discov Today; 2005 Nov; 10(22):1551-8. PubMed ID: 16257378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biomarkers in toxicology and risk assessment: informing critical dose-response relationships.
    Swenberg JA; Fryar-Tita E; Jeong YC; Boysen G; Starr T; Walker VE; Albertini RJ
    Chem Res Toxicol; 2008 Jan; 21(1):253-65. PubMed ID: 18161944
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utility of separation science in metabolomic studies.
    Issaq HJ; Abbott E; Veenstra TD
    J Sep Sci; 2008 Jun; 31(11):1936-47. PubMed ID: 18348322
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single cell metabolomics.
    Heinemann M; Zenobi R
    Curr Opin Biotechnol; 2011 Feb; 22(1):26-31. PubMed ID: 20934866
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proteomic applications in ecotoxicology.
    Monsinjon T; Knigge T
    Proteomics; 2007 Aug; 7(16):2997-3009. PubMed ID: 17703507
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Integrated Proteomic and Metabolomic prediction of Term Preeclampsia.
    Bahado-Singh R; Poon LC; Yilmaz A; Syngelaki A; Turkoglu O; Kumar P; Kirma J; Allos M; Accurti V; Li J; Zhao P; Graham SF; Cool DR; Nicolaides K
    Sci Rep; 2017 Nov; 7(1):16189. PubMed ID: 29170520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.